deCODE Genetics GeneHunger, Nemo, and Allegro are genetic drug discovery software programs that have been cited in the leading journals of the world, and several of deCODE's programs are also available to the scientific community. The company, which has employees in Iceland and the U.S., has available genealogical, genetic, and laboratory data that gives deCODE solutions to unusual challenges, which have had the effect of driving development of one-of-a-kind tools for management of haplotypes and family trees. For instance, Allegro software estimates the distance between DNA microsatellite markers. deCODE is the only one providing such a tool and is also doing things no other biotechnology company is doing. deCODE has quick access to patients who have already been characterized genetically and phenotypically, and deCODE's scientists have proprietary data and software for study of such samples. Therefore, deCODE can move discoveries to the clinic more quickly, even though the company has only 430 employees. deCODE has wasted no time in diligently mapping and publishing disease genes and advancing to the treatment formulation stage. Among topics covered are the DG-031 drug candidate trial (which investigated the leukotriene pathway that sets off inflammation and heart disease), the DG-041 program (a novel, first-in-class orally-administered small molecule for treating peripheral arterial disease), deCODE's many areas of therapeutic investigation, deCODE's uncanny ability to recruit scientific problem-solvers, and the deCODEs strategy for bringing drugs to market with a limited budget.